ZYBERNO
Stock Report
Updated Jun 8, 2026

4Front Ventures Corp. (FFNTF)

Healthcare • Over The Counter

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
5.0/100
POOR BUSINESS
4Front Ventures Corp. (FFNTF) scores 5/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-31.2%)
Return on Capital (Capital Efficiency):CRITICAL (-76.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

4Front Ventures Corp. (FFNTF) stock report — Zyberno Score 5/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$913.92

Valuation Multiples (2)

P/S Ratio:0.00x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$69.40M
B. Profitability Assessment

Return Metrics (4)

ROA:-13.4%
Reinvestment Rate:-57.5%
Fundamental Growth Rate (g):43.8%

Margin Analysis (3)

Operating Margin Ttm:-31.2%
Net Margin Ttm:-53.5%
Ebitda Margin:-17.6%

TTM Performance (3)

Gross Margin Ttm:50.9%
Operating Margin Ttm:-31.2%
Net Margin Ttm:-53.5%

Yield Metrics (2)

Earnings Yield:-$10.00M
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:77.1%
Latest Earnings Filed:2024-11-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-12.4%

Cash Flow Growth (Linear) (1)

Operating Cash Flow Growth Rate (Linear):-18.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.34x
Quick Ratio:0.16x
Cash Ratio:0.01x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-9.74x
Times Interest Earned:-9.74

Capital Structure (4)

Working Capital:-74,802,000.00
Cash And Cash Equivalents:1,246,000.00
Long Term Debt:$68.95M
Net Debt:$69.40M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $67.99M
Linear Growth: -12.4%
📊 Click to view full FFNTF Revenue analysis & methodology →
Cost Of Revenue Ttm:$73.87M

Profitability Breakdown (2)

Gross profit TTM: $34.61M
Linear Growth: -17.7%
📊 Click to view full FFNTF Gross Profit analysis & methodology →
-$21.24M

Bottom Line Performance (3)

-$36.40M
Income Before Tax:-$37.05M
Ebitda Ttm:-11,976,000.00

Operating Expenses (5)

Operating Expenses:44,263,000.00
R And D Expense:0.00
Sga Expense:51,447,000.00
Income Tax Expense:$6.27M
Interest Expense:2,141,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:300.3%
Ebitda Margin:-17.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$278.08M
Current Assets:$38.08M
Ppe Net:36,457,000.00
Goodwill:41,807,000.00
Intangible Assets:$25.67M

Liability Structure (4)

Total Liabilities:326,536,000.00
Current Liabilities:112,885,000.00
Long Term Debt:$68.95M
Short Term Debt:$1.69M

Equity & Capital (3)

Equity:-$48.45M
Retained Earnings:-$457.13M
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:5,707,000.00
Inventory:19,613,000.00
Accounts Payable:16,229,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:688,000.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $7.33M
Linear Growth: -18.1%
-$15.71M

Investment Activities (1)

Investing Cash Flow:-$1.77M

Financing Activities (3)

Financing Cash Flow:-$1.03M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:9,260,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.10
-$0.10
Earnings Per Share Ttm:-$0.04

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.07
Operating Cash Flow Per Share:-$0.00

Book Value & Capital (2)

Book Value Per Share:-$0.05
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.25x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:11.91x
Days Sales Outstanding Ttm:30.64

Inventory Management (2)

Inventory Turnover Ttm:3.77x
Days Inventory Outstanding Ttm:96.90

Payables & Cash Cycle (2)

Days Payable Outstanding:80.18
Cash Conversion Cycle:47.36
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-57.5%
Fundamental Growth Rate (g):43.8%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-12.4%

Cash Flow Growth Rates (1)

Operating Cash Flow Growth Rate (Linear):-18.1%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-17.7%
Book Value Growth Rate (Linear):-46.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:FFNTF
Company Name:4Front Ventures Corp.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:Over The Counter
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:913.92M
Shares Outstanding Basic:913.92M
Shares Outstanding Diluted:913.92M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-08 14:38:48 UTC
Data Timestamp:2026-06-08T14:38:48.172002
Scroll to Top